Nxera Pharma to Receive $8.6M Milestone Payment from Centessa for OX2R Development
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
Eli Lilly
Advertisement
Roche Wins FDA Clearance for Elecsys pTau217 Test
INDIANAPOLIS, U.S., Aug 28, 2026 Roche has received U.S. FDA clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217), a blood-based...
Eli Lilly Links Zepbound to Lower Healthcare Costs
Zepbound Use Associated With Lower Healthcare Costs INDIANAPOLIS, Aug. 26, 2026 — Eli Lilly and Company announced new real-world...
AlzeCure Receives $10M Upfront Payment From Lilly
Stockholm, Sweden, August 18, 2026 AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly...
Leal Therapeutics Advances LTX-001 in Schizophrenia Trial
Worcester, Massachusetts, August 17, 2026 Leal Therapeutics, a clinical-stage biopharmaceutical company developing neuro-metabolic therapeutics for central nervous system disorders,...
Advertisements
Lupin Wins FDA Approval for Pitolisant Tablets
Mumbai, India and Naples, Italy, August 17, 2026 Lupin Limited, a global pharmaceutical company, announced that it has received...
OmniAb and Lilly Advance Global Ion Channel Discovery
Emeryville, California, August 17, 2026 OmniAb, Inc. has announced a new global collaboration and license agreement with Eli Lilly...
Bridge to Life Raises $110M to Expand Organ Perfusion
DULUTH, Georgia, August 12, 2026 Bridge to Life Ltd., a medical technology company specializing in organ preservation and perfusion...
Eli Lilly Escalates Fight Against Illegal Retatrutide Market
INDIANAPOLIS, Indiana, August 12, 2026 Eli Lilly and Company has intensified its efforts to combat the illegal sale of...
Eli Lilly Reports Positive Phase 3 Retatrutide Results
INDIANAPOLIS, July 23, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3 TRIUMPH-2 and...
Advertisement
